X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Johnson & Johnson’s single-dose COVID-19 vaccine gets approval for emergency use in India

Content Team by Content Team
12th August 2021
in News
Johnson & Johnsons's single-dose COVID-19 vaccine gets approval for emergency use in India

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Johnson & Johnson’s (J&J) single-dose Covid-19 vaccine was on Saturday granted approval for emergency use in India. “India expands its vaccine basket. Johnson and Johnson’s single-dose Covid-19 vaccine is given approval for Emergency Use in India,” health minister Mansukh Mandaviya tweeted on Saturday. This is the fifth Covid-19 vaccine to be given emergency use approval in India and would further boost the nation’s collective fight against Covid-19, the minister said.

J&J had a week ago withdrawn its application for carrying out phase-3 clinical trials in India for its vaccine. This was after the Indian government waived this requirement for vaccines that had approvals from regulatory bodies in the US, UK, Europe and Japan. This was done to fast-track the vaccine approval process in the country and accelerate vaccination.

The country already has four vaccines approved so far, including Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V and Moderna, making J&J the fifth one. Moderna is yet to launch their vaccine in India. In India, J&J have a tie up with Biological E for technology transfer and manufacturing the Covid-19 vaccine in India.

J&J had been given emergency use authorisation by the US FDA in February this year. J&H also has Conditional Marketing Authorisation Application from the European Commission and got an Emergency Use Listing from the World Health Organization for its Covid-19 vaccine.

This single vaccine has been developed by the Janssen Pharmaceutical Companies of J&J. The J&J Covid-19 single-dose vaccine has to be stored at 2-8°C. According to J&J, their single-shot Covid-19 vaccine had demonstrated strong neutralising antibody activity against the rapidly spreading Delta variant . This variant is dominant in India. Their data showed that the durability of the immune response lasted through at least eight months. Overall the vaccine had an efficacy of 85% against severe and critical Covid-19 disease.

The country on Saturday crossed the 50-crore mark in vaccination administration. There were 38,628 daily new cases reported in the country taking the active case load to 4.12 lakh cases with a daily case positivity rate of 2.21%.

Previous Post

BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

Next Post

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In